S.C. Ropharma S.A (RPH) Fair Value & Analysis
Healthcare · RO · Market cap 102M RON
Fair value as of: Jun 24, 2026
From 17 valuation models · updated 23 days ago
Price vs Fair Value (12 months)
12‑month range 0.1580 RON – 0.2260 RON · fair‑value band 0.5500 RON – 1.70 RON · the 0.2000 RON price screens below the 0.9400 RON fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
S.C. Ropharma S.A (RPH) currently trades at 0.2000 RON, while our model-based Fair Value estimate is 0.9400 RON, implying the stock looks roughly 370.0% undervalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, S.C. Ropharma S.A generated revenue of 1.5B RON at a net margin of 0.1%. Revenue grew 20.1% year over year. It earns a return on equity of 2.6%. Net debt stands at 47.9M RON. Fundamentals as of Jun 24, 2026
Our scenario range runs from 0.5500 RON (bear case) to 1.70 RON (bull case); at 0.2000 RON, the current price sits below that range. The share trades about 12% below its 52-week high and 33% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 45% fair-value upside, at 370%, RPH screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
S.C. Ropharma S.A. operates a chain of pharmacies in Romania. The company distributes over-the-counter medications, food supplements, cosmetics, perfumes, medical devices, dermato-cosmetics, para pharmaceuticals, and other medicines through pharmaceutical warehouses. It also offers cardiovascular, dermatological, digestive, ophthalmological, osteoarticular, respiratory, urogenital, and diabetes medicines. In addition, the company provides supplements for immunity, antioxidants, vitamins and mineral medicines, and food and supplements for children, pregnancy, and breastfeeding medicines; and cosmetics for children, diapers, napkins, and protection against insects. Further, it offers body, hair, and skin care products; oral hygiene, solar protection, hand and foot care, and anti-insect products. Additionally, the company provides fertility, condoms, pregnancy and ovulation tests, and reproductive tonics; and medical equipment, protective glasses, and waterproof plasters. The company …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
S.C. Ropharma S.A reported revenue of 1.2B RON in FY2025 versus 718M RON in FY2021, a compound +13.5%/yr. Reported net income was −1.7M RON in FY2025.
Is RPH fairly valued? → Check now
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIF | $5.85 | $7.13 | +22% |
| Alibaba Health Information Technology Limited ALBBY | $8.56 | $6.91 | -19% |
| Raia Drogasil S.A RADL3 | R$16.79 | R$20.39 | +21% |
| Yifeng Pharmacy Chain Co 603939 | ¥19.75 | ¥29.07 | +47% |
| Clicks Group CLCGY | $28.55 | $41.54 | +45% |
| Sugi Holdings SGIPF | $16.29 | $64.34 | +295% |
| Corporativo Fragua, S.A. CGSBF | $29.66 | $40.69 | +37% |
| DaShenLin Pharmaceutical Group 603233 | ¥15.87 | ¥23.86 | +50% |
| Redcare Pharmacy NV RDC | €66.40 | €124.16 | +87% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥12.18 | ¥13.89 | +14% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is S.C. Ropharma S.A (RPH) undervalued?
What is the fair value of RPH?
What is the quality score of RPH?
What is the revenue of S.C. Ropharma S.A (RPH)?
What is the net profit margin of RPH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full S.C. Ropharma S.A analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.